dc.contributor.author
Klinghammer, Konrad
dc.contributor.author
Lorini, Luigi
dc.contributor.author
Nevens, Daan
dc.contributor.author
Simon, Christian
dc.contributor.author
Machiels, Jean-Pascal
dc.contributor.author
Bossi, Paolo
dc.date.accessioned
2022-08-30T08:57:09Z
dc.date.available
2022-08-30T08:57:09Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/36068
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-35784
dc.description.abstract
Multiple factors differentially influence treatment decisions in the first line treatment of recurrent/metastatic HNSCC. The EORTC Young investigator group launched a survey among treating physicians to explore the main influencing factors for treatment stratification. The questionnaire was posted as a web-survey link from May to August 2020. Next to defining the factors that mostly influence therapeutic decision the survey was complemented by a clinical case discussion of five patient cases. A total of 118 responses from 19 countries were collected. The key factors identified to guide treatment decision were performance status, PD-L1 Expression, time from last systemic treatment above or below 6 months, and disease burden.Prospective evaluation of patient characteristics and additional potential predictive biomarkers for novel treatment options remains an important question to stratify personalized treatment for RM HNSCC.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
head and neck squamous cell carcinoma
en
dc.subject
treatment stratification
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer Group
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
730785
dcterms.bibliographicCitation.doi
10.3389/fonc.2022.730785
dcterms.bibliographicCitation.journaltitle
Frontiers in Oncology
dcterms.bibliographicCitation.originalpublishername
Frontiers Media SA
dcterms.bibliographicCitation.volume
12
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
35155222
dcterms.isPartOf.eissn
2234-943X